Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Get Free Report) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 9,400 shares, a decrease of 15.3% from the March 31st total of 11,100 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 31,300 shares, the short-interest ratio is presently 0.3 days.
Institutional Trading of Sol-Gel Technologies
A hedge fund recently bought a new position in Sol-Gel Technologies stock. Yelin Lapidot Holdings Management Ltd. acquired a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 229,178 shares of the company’s stock, valued at approximately $374,000. Yelin Lapidot Holdings Management Ltd. owned 0.99% of Sol-Gel Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 26.18% of the company’s stock.
Sol-Gel Technologies Trading Down 18.7 %
Shares of SLGL opened at $0.71 on Wednesday. The company’s fifty day simple moving average is $1.00 and its 200-day simple moving average is $1.18. The company has a market cap of $19.85 million, a P/E ratio of -0.77 and a beta of 1.33. Sol-Gel Technologies has a twelve month low of $0.71 and a twelve month high of $4.05.
Sol-Gel Technologies Company Profile
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Further Reading
- Five stocks we like better than Sol-Gel Technologies
- How to Calculate Options Profits
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Stock Sentiment Analysis: How it Works
- Hilton Demonstrates Asset Light is Right for Investors
- The 3 Best Fintech Stocks to Buy Now
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.